45results about How to "Blocking interaction" patented technology

The invention discloses a preparation method of an anti-tobacco potato Y virus vaccine. The method includes the following steps that 1, pCaPVX440-eIF4E-6 plasmids are prepared; 2, the pCaPVX440-eIF4E-6 is transferred to agrobacterium to prepare the anti-tobacco potato Y virus vaccine. The anti-tobacco potato Y virus vaccine prepared by means of the preparation method is suitable for prevention and control of tobacco PVY viruses and has an important practical value for prevention and control of diseases caused by the PVY viruses in the tobacco leaf production process. Compared with the prior art, the virus vaccine is good in specificity, good in safety, simple, convenient and quick to operate and low in cost.

The invention belongs to the technical field of biological medicines and relates to a detection kit for human leucocyte antigen (HLA) genes--HLA-B*59: 01 genes, and the HLA-B*59: 01 genes can serve as marker genes for forecasting methazolamide caused SJS (Stevens-Johnson syndrome) and TEN (Toxic epidermal necrolysis). According to the detection kit, after DNA extracted from the peripheral blood of a patient, the PCR-SSO method is adopted to detect the HLA-B*59 :01 genes. The detection kit for HLA-B*59: 01 genes can be used for examining before application of methazolamide and screening targeted medicines for treating methazolamide caused SJS and TEN; and examination can guide clinical medication to reduce incidence of SJS and TEN caused by methazolamide, and the screening mainly acts on HLA-B*59: 01 molecules in a targeted manner, so that interaction between the HLA-B*59: 01 molecules and methazolamide or other metabolic products during attack.

The invention provides a human leukocyte antigen gene detection kit for screening skin drug adverse reaction caused by salazosulfapyridine, belongs to the technical field of biomedicine, and relates to a detection kit of human leukocyte antigen gene HLA-B*13:01, wherein the HLA-B*13:01 gene can be adopted as the marker gene of salazosulfapyridine-induced DRESS. According to the present invention, DNA is extracted from the peripheral blood of a patient, and the HLA-B*13:01 gene is detected by using the current method, such as PCR-SSO (sequence-specific oligonucleotide probe) method; and the HLA-B*13:01 gene detection kit of the present invention can be used for screening before the salazosulfapyridine use and screening the target drug for treatment of salazosulfapyridine-induced DRESS, wherein the screening before the salazosulfapyridine use can guide the clinical medication so as to reduce the occurrence of the salazosulfapyridine-induced DRESS, and the drug screening mainly act on the HLA-B*13:01 molecules in a targeting manner so as to block the interaction between the HLA-B*13:01 molecules and the salazosulfapyridine or the metabolites thereof in the pathogenesis.

The invention relates to a compound of a blocking agent for CD47/SIRP alpha interaction, in particular to a compound as shown in a formula I, a medicine composition containing the compound as shown inthe formula I and an application of the compound to treatment of CD47/SIRP alpha interaction mediated diseases and preparation of a medicine for treating the CD47/SIRP alpha interaction mediated diseases.

The invention discloses an anti-TIGIT nanobody and application thereof, and particularly provides an anti-TIGIT nanobody and a sequence thereof. The invention also provides a coding sequence encodingthe nanobody or a VHH chain thereof, a corresponding expression vector and a host cell capable of expressing the nanobody, as well as a production method of the nanobody. The nanobody can block the interaction between TIGIT and CD155 on the surface of CT26 cells, and can effectively bind to the TIGIT protein on the cell surface; the nanobody can recognize human and macaca fascicularis TIGIT; the blocking activity of the nanobody is significantly better than a control antibody Tiragolumab; and the nanobody has a significant activating effect on T cells, and the activation effect is significantly better than that of the control antibody Tiragolumab.

The invention belongs to the technical field of biological medicine, and relates to a human leukocyte antigen HLA-B*51: 01 gene detection kit. An HLA-B*51: 01 gene can be used as a marker gene for predicting clindamycin-induced drug rash. The invention provides the application of the detection kit to typing of the HLA-B*51: 01 gene in a sample. The application comprises the following steps: extracting DNA from obtained peripheral blood of a patient, and detecting the HLA-B*51: 01 gene by a current method, such as a sequence-specific oligonucleotide probe (PCR-SSO) method. The HLA-B*51: 01 gene detection kit provided by the invention can be applied to screening and sifting of targeted drugs for treating the clindamycin-induced drug rash before the use of clindamycin; screening application can guide clinical drug use so as to reduce incidence of the clindamycin-induced drug rash; selecting application mainly acts on an HLA-B*51: 01 molecule in a targeted manner so as to block interaction between the HLA-B*51: 01 molecule and clindamycin or other metabolites during the drug rash.

The invention relates to a photoelectric material and a preparation method thereof, particularly to a fluorenyl aromatic phosphine oxide photoelectric material and a preparation method thereof, and aims at solving the problem that carrier injection transmission is unbalanced caused by the fact that aromatic hydrocarbon or arylamine functional groups with large conjugated structures are introduced into a fluorine system. The method includes preparing 2-bromine-(9,9-bis-(diphenylphosphine oxide) ) fluorine; and mixing the 2-bromine-(9,9-bis-(diphenylphosphine oxide) ) fluorine, tetrakis (triphenylphosphine) palladium, tetrabutylammonium bromide and borate and dissolving in tetrahydrofuran, adding in NaOH solution, and obtaining the photoelectric material after reaction, extraction, drying and column chromatography; or mixing the 2-bromine-(9,9-bis-(diphenylphosphine oxide) ) fluorine, carbazole, potassium carbonate, copper iodide and 18-crown-6-ether, adding in a high-temperature solvent, and obtaining the photoelectric material after reaction, extraction, drying and column chromatography. The power efficiency of the photoelectric material prepared through the method can reach 2.19lm/W when the material is used for preparing blue-ray fluorescent devices.

The invention relates to a hybridoma cell strain SZ-125(3D2) with the prevention number of CGMCC NO.2501 and a bi-functional monoclonal antibody capable of anti-human von willbrand factor-A3 secreted by the hybridoma cell strain. The monoclonal antibody is combined with the VWF A3 to block the combination of the VWF A3 and collagen and simultaneously influences the configuration of domain A1, thereby destroying the original domain A1 configuration capable of combining platelet GPIb alpha and achieving the aim of blocking the interaction of the VWF A1 and the GPIb alpha, so that not only combination of the VWF A3 and the collagen is blocked but also the combination of the VWF A1 and the platelet GPIb alpha is blocked. Thus, the monoclonal antibody can be used for preparing anti-artery thrombosis medicine with anti-platelet adhesion activity.

The invention discloses application of HLA-A*24:02 allele to detecting person drug eruption risk caused by metronidazole. The invention provides application of a substance for detecting whether persons have the HLA-A*24:02 allele or not to preparing a product for detecting or evaluating adverse drug reaction risk generated when persons respond to the metronidazole. Experiments show that the humanleukocyte antigen gene-HLA-A*24:02 allele is related to drug eruptionattacking caused by the metronidazole. The HLA-A*24:02 allele can serve as a marker gene for forecasting the drug eruption risk caused by the metronidazole.

The invention relates to an anti-SIRP alpha rabbit recombinant monoclonal antibody as well as a preparation method and application thereof, amino acid sequences of heavy chain complementary determining regions HCDR1, HCDR2 and HCDR3 of the anti-SIRP alpha rabbit recombinant monoclonal antibody are amino acid sequences as shown in SEQ ID NO: 1, SEQ ID NO: 2 and SEQ ID NO: 3 respectively, and amino acid sequences of light chain complementary determining regions LCDR1, LCDR2 and LCDR3 are amino acid sequences as shown in SEQ ID NO: 4, SEQ ID NO: 5 and SEQ ID NO: 6 respectively. The anti-SIRP alpha rabbit recombinant monoclonal antibody has good specificity, can be used in ELISA (Enzyme-Linked Immunosorbent Assay) and a common flow detection method, most importantly, the antibody can block the interaction between CD47 protein and SIRP alpha protein, and has potential tumor immunotherapy value.

The invention provides a mineralization material for preventing and treating dentin hypersensitivity and resisting caries as well as a preparation method and application thereof, and belongs to the technical field of dental materials. The mineralization material for preventing and treating dentin hypersensitivity and resisting caries is a calcium phosphate nano biomimetic mineralization material loaded with egg yolk immunoglobulin, can effectively seal exposed dentin tubules, can effectively inhibit growth of cariogenic bacteria streptococcus mutans, and has good safety.